Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17;11(2):e39778.
doi: 10.2196/39778.

Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Reza Rahmani #  1 , Ehsan Moradi Farsani #  1 , Sima Bahrami #  1
Affiliations

Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Reza Rahmani et al. Interact J Med Res. .

Abstract

Background: Recurrent angina, which is defined as a return of chest pain or chest discomfort, occurs in many patients undergoing coronary interventions.

Objective: This study aims to compare the antianginal efficacy of ranolazine versus allopurinol for eligible symptomatic patients with a history of angioplasty.

Methods: A total of 62 eligible symptomatic patients with a history of angioplasty were randomly allocated into two groups. For group A, 300 mg of allopurinol was administered twice daily, while for group B, 1000 mg of ranolazine daily was prescribed for a duration of 4 weeks. An initial screening visit was done for all participants where patients' medical history was recorded and a physical examination was given; electrocardiography, blood pressure, and heart rate measurements were done as well. The patients were also given a blood and exercise test. At the end of the medication period, participants were revisited, and the tests were done again. All the required data were collected via a researcher-made form, and data analysis was conducted using SPSS. The study was approved by a formal ethics committee.

Results: The mean age of participants in the two groups (A and B) was 57.36 (SD 8.36) and 60.27 (SD 9.17) years, respectively. Among the 62 patients, 34 (59%) were men, while 28 (41%) were women. Creatinine, fasting blood sugar, C-reactive protein, N-terminal prohormone of brain natriuretic protein, uric acid, white blood cell, and hemoglobin levels of participants were not significantly different between groups (P>.05). Both allopurinol and ranolazine increased the total exercise time and decreased the ST depression of the patients. Additionally, they both improved the chest pain severity and Duke Treadmill Score of patients. At the same time, ranolazine had a statistically greater effect on ST depression reduction (mean 2.64, SD 0.74 vs mean 1.57, SD 0.49), while allopurinol showed better efficacy in reducing chest pain severity (mean 1.86, SD 0.37 vs mean 0.59, SD 0.21) and the Duke Treadmill Score (mean -14.77, SD 3.65 vs mean -6.88, SD 1.93).

Conclusions: Based on the results, the antianginal efficacy of allopurinol and ranolazine was approved but with different effects on ST depression, chest pain severity, and the Duke Treadmill Score. Therefore, the precise differences in their effects need to be explored further.

Keywords: allopurinol; exercise tolerance; ranolazine; recurrent angina.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

Figure 1
Figure 1
The study procedure.
See this image and copyright information in PMC

References

    1. Shahsavari S, Nazari F, Karimyar JM, Sadeghi M. Epidemiologic study of hospitalized cardiovascular patients in Jahrom hospitals in 2012-2013. Cardiovasc Nurs J. 2013:14–21. http://journal.icns.org.ir/article-1-173-en.html
    1. Yousefnejhad K, Masoumi S. Evaluation of long-term clinical outcome of metal stent angioplasty in patients with coronary artery disease in Sari Fetemeh Zahra hospital from 2004 to 2006. Med J Mazandaran University Med Sci. 2007;17(62):21–30. https://jmums.mazums.ac.ir/article-1-453-fa.pdf
    1. Izzo P, Macchi A, De Gennaro L, Gaglione A, Di Biase M, Brunetti ND. Recurrent angina after coronary angioplasty: mechanisms, diagnostic and therapeutic options. Eur Heart J Acute Cardiovasc Care. 2012 Jul;1(2):158–69. doi: 10.1177/2048872612449111. https://europepmc.org/abstract/MED/24062904 10.1177_2048872612449111 - DOI - PMC - PubMed
    1. Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol. 2011 Aug 16;58(8):820–8. doi: 10.1016/j.jacc.2010.12.052. https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)01948-6 S0735-1097(11)01948-6 - DOI - PubMed
    1. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA, MARISA Investigators Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004 May 21;43(8):1375–82. doi: 10.1016/j.jacc.2003.11.045. https://linkinghub.elsevier.com/retrieve/pii/S0735109704001925 S0735109704001925 - DOI - PubMed